Fluoroquinolone prophylaxis in autologous hematopoietic stem cell transplant recipients

[1]  J. Bartlett,et al.  Oral norfloxacin for prevention of gram-negative bacterial infections in patients with acute leukemia and granulocytopenia. A randomized, double-blind, placebo-controlled trial. , 2020, Annals of internal medicine.

[2]  A. Deol,et al.  BEAM Conditioning Regimen Has Higher Toxicity Compared With High-Dose Melphalan for Salvage Autologous Hematopoietic Stem Cell Transplantation in Multiple Myeloma. , 2015, Clinical lymphoma, myeloma & leukemia.

[3]  H. Nakasone,et al.  Antibiotic prophylaxis in hematopoietic stem cell transplantation. A meta-analysis of randomized controlled trials. , 2014, The Journal of infection.

[4]  M. Sanz,et al.  Incidence, risk factors, and outcome of bacteremia following autologous hematopoietic stem cell transplantation in 720 adult patients , 2014, Annals of Hematology.

[5]  Â. Maiolino,et al.  Ciprofloxacin prophylaxis in high risk neutropenic patients: effects on outcomes, antimicrobial therapy and resistance , 2013, BMC Infectious Diseases.

[6]  Junshik Hong,et al.  Comparison of characteristics of bacterial bloodstream infection between adult patients with allogeneic and autologous hematopoietic stem cell transplantation. , 2013, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[7]  T. Robak,et al.  Ciprofloxacin prophylaxis for patients undergoing high-dose chemotherapy and autologous stem cell transplantation (ASCT) - a single-center experience. , 2012, Advances in medical sciences.

[8]  G. Wassmer,et al.  Efficacy and safety of moxifloxacin as antibacterial prophylaxis for patients receiving autologous haematopoietic stem cell transplantation: a randomised trial. , 2012, International journal of antimicrobial agents.

[9]  L. Leibovici,et al.  Antibiotic prophylaxis for bacterial infections in afebrile neutropenic patients following chemotherapy. , 2012, The Cochrane database of systematic reviews.

[10]  K. Lee,et al.  The role of prophylactic antimicrobials during autologous stem cell transplantation: a single-center experience , 2011, European Journal of Clinical Microbiology & Infectious Diseases.

[11]  K. Sepkowitz,et al.  Clinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer: 2010 update by the infectious diseases society of america. , 2011, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[12]  M. Dimopoulos,et al.  Prophylactic antibiotics for the prevention of neutropenic fever in patients undergoing autologous stem‐cell transplantation: Results of a single institution, randomized phase 2 trial , 2010, American journal of hematology.

[13]  L. Leibovici,et al.  Effect of quinolone prophylaxis in afebrile neutropenic patients on microbial resistance: systematic review and meta-analysis. , 2006, The Journal of antimicrobial chemotherapy.

[14]  J. Bartlett,et al.  The new Clostridium difficile--what does it mean? , 2005, The New England journal of medicine.

[15]  L. Lanthier,et al.  Emergence of fluoroquinolones as the predominant risk factor for Clostridium difficile-associated diarrhea: a cohort study during an epidemic in Quebec. , 2005, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[16]  R. Foà,et al.  Levofloxacin to prevent bacterial infection in patients with cancer and neutropenia. , 2005, The New England journal of medicine.

[17]  R. Huddart,et al.  Antibacterial prophylaxis after chemotherapy for solid tumors and lymphomas. , 2005, The New England journal of medicine.

[18]  Robin Patel,et al.  Bacteremia due to viridans group Streptococci with diminished susceptibility to Levofloxacin among neutropenic patients receiving levofloxacin prophylaxis. , 2002, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[19]  K. Sepkowitz,et al.  Infections caused by viridans streptococci in patients with neutropenia. , 2002, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[20]  C. Schmid,et al.  Early infection in bone marrow transplantation: quantitative study of clinical factors that affect risk. , 1999, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[21]  L. Young,et al.  1997 guidelines for the use of antimicrobial agents in neutropenic patients with unexplained fever. Infectious Diseases Society of America. , 1997, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[22]  T. Calandra,et al.  Escherichia coli resistant to fluoroquinolones in patients with cancer and neutropenia. , 1994, The New England journal of medicine.

[23]  J. Verhoef,et al.  Prevention of infections in the neutropenic patient. , 1993, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[24]  M. Thornquist,et al.  The effects of infection prevention regimens on early infectious complications in marrow transplant patients: A four arm randomized study , 1988, Infection.

[25]  T. Louie,et al.  Comparison of norfloxacin with cotrimoxazole for infection prophylaxis in acute leukemia. The trade-off for reduced gram-negative sepsis. , 1988, The American journal of medicine.

[26]  H. Einsele,et al.  The Prospective Oral Mucositis Audit: relationship of severe oral mucositis with clinical and medical resource use outcomes in patients receiving high-dose melphalan or BEAM-conditioning chemotherapy and autologous SCT , 2009, Bone Marrow Transplantation.

[27]  C. Hsueh,et al.  Low infectious morbidity in patients with heavily pretreated hematological malignancies receiving autologous peripheral blood stem cell transplantation without antimicrobial prophylaxis , 2002, Annals of Hematology.

[28]  R. Salazar,et al.  Infectious complications in 126 patients treated with high-dose chemotherapy and autologous peripheral blood stem cell transplantation , 1999, Bone Marrow Transplantation.

[29]  C. C. Patrick.  Use of fluoroquinolones as prophylactic agents in patients with neutropenia. , 1997, The Pediatric infectious disease journal.

[30]  M. Avril,et al.  Antiinfective prophylaxis with ceftazidime and teicoplanin in children undergoing high-dose chemotherapy and bone marrow transplantation. , 1994, Pediatric hematology and oncology.

[31]  F. Menichetti,et al.  The new fluorinated quinolones for antimicrobial prophylaxis in neutropenic cancer patients. , 1993, European journal of cancer.